New pathogenetic aspects of the relationship between some risk factors of cerebrovascular diseases and Parkinson’s disease

V.N. Gertsev, A.N. Stoyanov, S.S. Mashchenko, S.A. Antonenko


Role of the disorders of the autonomous nervous system in the development of cerebrovascular diseases and Parkinson’s disease is studied not enough until now. In a number of works it was found that diabetes, history of smoking, high blood pressure, increased level of glucose, cholesterol and triglycerides in the blood are considerably rarer observed in patients with idiopathic Parkinson’s disease. It is also reported about the reduced risk of stroke development in patients with Parkinson’s disease. At the same time, in other works it was found that the risk of stroke in patients with Parkinson’s disease increases, and diabetes and high blood pressure are associated with increased risk of developing this disease. It is also known that Parkinson’s disease and cardiovascular risk factors are independent factors for the development of cognitive disorders. Rеsults of works about the influence of statins on the onset and course of Parkinson’s disease are controversial. These contradictions partly can be explained by possible influence of fungal flora that, as known, is widely presented in patients with Parkinson’s disease. It is known that statins are produced by fungal microorganisms. Changes in the intestinal microbiota play a significant role in pathogenesis of Parkinson’s disease; gastrointestinal disorders in Parkinson’s disease are one of the first non-motor symptoms, which appear a few years before typical clinical presentation. In this case, small intestinal dysbiosis in most patients is associated with malabsorption due to high bacterial density. Thus, analyzing the above mentioned, it is possible to assume that intestinal and skin microbiota produces natural statins, and the use of antiparkinson and other drugs influences this function, that is why results of researches are contradictory. Studying etiopathogenesis of this relations requires further interdisciplinary researches on the base of evidential medicine. Perspective direction in the study of etiology and pathogenesis of Parkinson’s disease is a deep evaluation of the role of fungal microflora. A study of the relationships given above will allow us to identify new biomarkers and drug targets for the development of disease-modifying therapies.


Parkinson’s disease; autonomous system; cerebrovascular disease; blood lipids; fungal microflora


Scigliano G., Ronchetti G., Girotti F. Autonomic nervous system and risk factors for vascular disease. Effects of autonomic unbalance in schizo-phrenia and Parkinson's disease. Neurol. Sci. 2008 Feb. Vol. 29(1). P. 15-21. doi: 10.1007/s10072-008-0853-1. Epub 2008 Apr 1.

Scigliano G., Musicco M., Soliveri P., Piccolo I., Ronchetti G., Girotti F. Reduced risk factors for vascular disorders in Parkinson disease pa-tients: a case-control study. Stroke. 2006 May. Vol. 37(5). P. 1184-8. Epub 2006 Mar 30.

Scigliano G., Ronchetti G., Girotti F., Musicco M. Sympathetic modulation by levodopa reduces vascular risk factors in Parkinson di-sease. Parkinsonism Relat. Disord. 2009 Feb. Vol. 15(2). P. 138-43. doi: 10.1016/j.parkreldis.2008.04.036. Epub 2008 Jun 16.

Korten A., Lodder J., Vreeling F., Boreas A., van Raak L. et al. Stroke and idiopathic Parkinson’s disease: Does a shortage of dopamine offer protection against stroke? Mov. Disord. 2001. Vol. 16. P. 119-123.

Struck L.K., Rodnitzky R.L., Dobson J.K. Stroke and its modification in Parkinson’s disease. Stroke. 1990. Vol. 21. P. 1395-1399.

Huang Y.-P., Chen L.-S., Yen M.-F., Fann C.-Y., Chiu Y.-H., Chen H.-H. et al. Parkinson’s Disease Is Related to an Increased Risk of Ischemic Stroke — A Population-Based Propensity Score-Matched Follow-Up Study. PLoS One. 2013. Vol. 8(9). e68314.

Cereda E., Barichella M., Cassani E., Caccialanza R., Pezzoli G. Clinical features of Parkinson disease when onset of diabetes came first. Neu-rology. 2012. Vol. 78. P. 1507-1511.

Schernhammer E., Hansen J., Rugbjerg K., Wermuth L., Ritz B. Diabetes and the Risk of Developing Parkinson’s Disease in Denmark. Diabetes Care. 2011. Vol. 34. P. 1102-1108.

Sun Y., Chang Y.H., Chen H.F., Su Y.H., Su H.F. et al. Risk of Parkinson Disease Onset in Patients With Diabetes. Diabetes Care. 2012. Vol. 35. P. 1047-1049.

Cereda E., Barichella M., Pedrolli C., Klersy C., Cassani E. et al. Diabetes and Risk of Parkinson’s Disease. Diabetes Care. 2011. Vol. 34. P. 2614-2623.

Qiu C., Hu G., Kivipelto M., Laatikainen T., Antikainen R. et al. Association of Blood Pressure and Hypertension With the Risk of Parkinson Disease. Hypertension 2011. Vol. 57. P. 1094-1100.

Rönnemaa T. Intensive glycemic control and macrovascular disease in type 2 diabetes: a report on the 44th Annual EASD Meeting, Rome, Ita-ly, September 2008. Rev. Diabet. Stud. 2008. Vol. 5. P. 180-183. pmid: 19099091.

Jones J.D., Tanner J.J., Okun M., Price C.C., Bowers D. Are Parkinson’s Patients More Vulnerable to the Effects of Cardiovascular Risk: A Neuroimaging and Neuropsychological Study. J. Int. Neuropsychol. Soc. 2017 Apr. Vol. 23(4). P. 322-331. doi: 10.1017/S1355617717000017. Epub 2017 Feb 6.

Huang X., Alonso A., Guo X., Umbach D.M., Lichtenstein M.L., Ballantyne C.M., Mailman R.B., Mosley T.H., Chen H. Statins, plasma choles-terol, and risk of Parkinson’s disease: a prospective study. Mov. Disord. 2015 Apr. Vol. 30(4). P. 552-9. doi: 10.1002/mds.26152. Epub 2015 Jan 14.

Liu G., Sterling N.W., Kong L., Lewis M.M., Mailman R.B., Chen H., Leslie D., Huang X. Statins may facilitate Parkinson’s di-sease: Insight gained from a large, national claims database. Mov. Di­sord. 2017 Jun. Vol. 32(6). P. 913-917. doi: 10.1002/mds.27006. Epub 2017 Apr 3.

Bykov K., Yoshida K., Weisskopf M.G., Gagne J.J. Confoun­ding of the association between statins and Parkinson disease: systematic review and meta-analysis. Pharmacoepidemiol. Drug Saf. 2017 Mar. Vol. 26(3). P. 294-300. doi: 10.1002/pds.4079. Epub 2016 Aug 16.

Gudala K., Bansal D., Muthyala H. Role of serum cholesterol in Parkinson’s disease: a meta-analysis of evidence. J. Parkinsons Dis. 2013 Jan 1. Vol. 3(3). P. 363-70. doi: 10.3233/JPD-130196.

Xicoy H., Wieringa B., Martens G.J.M. The Role of Lipids in Parkinson’s Disease. Cells. 2019 Jan 7. Vol. 8(1). pii: E27. doi: 10.3390/cells8010027.

Seyfried T.N., Choi H., Chevalier A., Hogan D., Akgoc Z., Schneider J.S. Sex-Related Abnormalities in Substantia Nigra Lipids in Parkinson’s Disease. ASN Neuro. 2018. Vol. 10. doi: 10.1177/1759091418781889.

Kurup R.K., Kurup P.A. Hypothalamic digoxin-mediated model for Parkinson’s disease. Int. J. Neurosci. 2003. Vol. 113. P. 515-536. doi: 10.1080/00207450390162263.

Broxmeyer L. Parkinson’s: another look. Med. Hypotheses. 2002. Vol. 59(4). P. 373-377.

Ухолкина Г.Б. Статины — прошлое, настоящее, будущее. Ліки України. 2013. № 4. С. 45-50.

Campbell C.D., Vederas J.C. Biosynthesis of lovastatin and related metabolites formed by fungal iterative PKS enzymes. Biopolymers. 2010. Vol. 93. P. 755-763. doi:10.1002/bip.21428.

Guihong Yu, Shuai Wang, Lu Wang, Qian Che, Tianjiao Zhu, Guojian Zhang, Qianqun Gu, Peng Guo, and Dehai Li. Lipid-Lowering Polyke-tides from the Fungus Penicillium Steckii HDN13-279. Mar. Drugs. 2018. Vol. 16. P. 25. doi: 10.3390/md16010025.

Joong-Seok Kim, Hye-Young Sung. Gastrointestinal Autonomic Dysfunction in Patients with Parkinson’s Disease. JMD. 2015. Vol. 8(2). P. 76-82.

Ferrer I., Martinez A., Blanco R., Dalfó E., Carmona M. Neuropathology of sporadic Parkinson disease before the appearance of parkinson-ism: preclinical Parkinson disease. J. Neural. Transm. 2011. Vol. 118. P. 821-839.

Gasbarrini A., Lauritano E.C., Gabrielli M., Scarpellini E., Lupascu A., Ojetti V. et al. Small intestinal bacterial overgrowth: diagnosis and treatment. Dig. Dis. 2007. Vol. 25. P. 237-240.

Gabrielli M., Bonazzi P., Scarpellini E., Bendia E., Lauritano E.C., Fasano A. et al. Prevalence of small intestinal bacterial overgrowth in Par-kinson’s disease. Mov. Disord. 2011. Vol. 26. P. 889892.

Fasano A., Bove F., Gabrielli M., Petracca M., Zocco M.A., Ragazzoni E. et al. The role of small intestinal bacterial overgrowth in Parkinson’s disease. Mov. Disord. 2013. Vol. 28. P. 1241-1249.

Dobbs R.J., Charlett A., Dobbs S.M., Weller C., Ibrahim M.A., Iguodala O. et al. Leukocyte-subset counts in idiopathic parkinsonism provide clues to a pathogenic pathway involving small intestinal bacterial overgrowth. A surveillance study. Gut. Pathog. 2012. Vol. 4. P. 12.

Dobbs S.M., Charlett A., Dobbs R.J., Weller C., Iguodala O., Smee C. et al. Antimicrobial surveillance in idiopathic parkinsonism: indication-specific improvement in hypokinesia following Helicobacter pylori eradication and non-specific effect of antimicrobials for other indications in worsening rigidity. Helicobacter. 2013. Vol. 18. P. 187-196.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.


© Publishing House Zaslavsky, 1997-2020


   Seo анализ сайта